Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
May 06, 2024 08:00 ET
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
Dermatology Collaboration and Licensing Deals Report, 2016 to 2024, Featuring 600+ Companies and 400+ Deals
May 02, 2024 07:33 ET
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Dermatology Collaboration and...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
May 02, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294...
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
May 01, 2024 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
April 30, 2024 09:00 ET
|
Kamari Pharma
NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
Europe Scar Management Market Analysis Report 2024: A $350+ Million Market by 2030 with Advancis Medical, Bayer, B. Braun, Molnlycke Health Care, Smith & Nephew, and Stratpharma Dominating
April 29, 2024 10:07 ET
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Europe Scar Management Market: Analysis and Forecast, 2023-2030" report has been added to ResearchAndMarkets.com's offering. The Europe scar...
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
April 25, 2024 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Global Skin Allergy Testing Market Report 2024-2028 with Analysis of Companies' Market Shares, Proprietary Technologies, Alliances and Patents
April 24, 2024 06:14 ET
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Global Skin Allergy Testing Market" report has been added to ResearchAndMarkets.com's offering.The global market for skin allergy testing is expected...
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten...
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
April 17, 2024 10:15 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...